Comparative Pharmacology
Head-to-head clinical analysis: EXNA versus MODURETIC 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXNA versus MODURETIC 5 50.
EXNA vs MODURETIC 5-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI): inhibits serotonin (5-HT) reuptake at the presynaptic neuron, increasing serotonin availability in the synaptic cleft.
Combination diuretic: amiloride blocks epithelial sodium channels (ENaC) in distal tubule, inhibiting sodium reabsorption and potassium excretion; hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
EXNA is not a recognized drug; no standard dosing available.
1 tablet (5 mg amiloride/50 mg hydrochlorothiazide) orally once daily, increased if needed to 2 tablets daily as a single dose or divided doses.
None Documented
None Documented
Terminal elimination half-life 12-18 hours (mean 14 h) in adults; prolonged in renal impairment (up to 30-40 h in CrCl <30 mL/min).
HCTZ: 5.6-14.8 hours; amiloride: 6-9 hours. Both prolonged in renal impairment (e.g., creatinine clearance <30 mL/min). Terminal elimination half-life for HCTZ may extend to >20 hours in severe renal disease.
Primarily renal (70% unchanged drug; 15% as metabolites); biliary/fecal (10%); <5% in breast milk.
Both components are primarily excreted renally: hydrochlorothiazide (HCTZ) ~70% unchanged in urine; amiloride ~50% unchanged in urine. Minor biliary/fecal elimination (<10% for each).
Category C
Category C
Diuretic
Diuretic